| Literature DB >> 23035864 |
Ibrahim Akin1, Stephan Kische, Lylia Paranskaya, Henrik Schneider, Tim C Rehders, Ulrich Trautwein, Gökmen Turan, Dietmar Bänsch, Olga Thiele, Dimitar Divchev, Ilkay Bozdag-Turan, Jasmin Ortak, Gunther Kundt, Christoph A Nienaber, Hüseyin Ince.
Abstract
BACKGROUND: Transcatheter aortic valve implantation (TAVI) has been established as a treatment option for inoperable patients with symptomatic aortic valve stenosis. However, patients suffer frequently from conduction disturbances after TAVI.Entities:
Mesh:
Year: 2012 PMID: 23035864 PMCID: PMC3509406 DOI: 10.1186/1471-2261-12-87
Source DB: PubMed Journal: BMC Cardiovasc Disord ISSN: 1471-2261 Impact factor: 2.298
Baseline characteristics of study population stratified in pacemaker (PM) and non pacemaker group (N-PM)
| Clinical parameters | |||
| Male, n (%) | 10 (43.5) | 8 (36.4) | 0.763 |
| Age (yrs) | 80.7 ± 5.94 | 81.55 ± 7.90 | 0.684 |
| Body mass index (kg/m2) | 26.9 ± 3.9 | 26.8 ± 4.0 | 0.883 |
| Hypertension, n (%) | 22 (95.7) | 19 (86.4) | 0.346 |
| Smoker, n (%) | 8 (34.8) | 4 (18.2) | 0.024 |
| Diabetes mellitus, n (%) | 10 (43.5) | 7 (31.8) | 0.542 |
| Creatinine (μmol/l) | 151.2 ± 157.4 | 114.3 ± 51.6 | 0.372 |
| Renal insufficiency (creatinine level > 1.5mg/dl), n (%) | 14 (60.9) | 11 (50) | 0.554 |
| Chronic obstructive pulmonary disease, n (%) | 4 (17.1) | 4 (18.2) | 0.855 |
| New York Heart Association functional class | |||
| I | 0 (0) | 0 (0) | 0.263 |
| II | 0 (0) | 2 (9.1) | |
| III | 15 (65.2) | 15 (68.2) | |
| IV | 8 (34.8) | 5 (22.7) | |
| Logistic EuroSCORE (%) | 24.0 ± 14.6 | 18.4 ± 19.2 | 0.034 |
| Dyspnoe, n (%) | 13 (56.6) | 12 (54.6) | 0.628 |
| Angina, n (%) | 11 (47.5) | 6 (27.3) | 0.022 |
| Syncope, n (%) | 3 (13.0) | 8 (36.4) | 0.091 |
| Pulmonal artery pressure (mmHg) | 42.8 ± 17.7 | 37.6 ± 19.9 | 0.375 |
| Porcelain aorta, n (%) | 1 (4.3) | 3 (13.6) | 0.346 |
| Prior cardiac decompensation, n (%) | 13 (56.5) | 14 (63.7) | 0.763 |
| Ischemic heart disease, n (%) | 20 (87.0) | 15 (68.2) | 0.017 |
| Previous stroke, n (%) | 10 (43.5) | 3 (13.6) | 0.047 |
| Previous CABG, n (%) | 1 (4.3) | 2 (9.1) | 0.838 |
| Peripheral vessel disease, n (%) | 5 (21.7) | 1 (4.6) | 0.002 |
| Echocardiographic parameters | |||
| Mean aortic valve area (cm2) | 0.8 ± 0.2 | 0.7 ± 0.2 | 0.108 |
| Left ventricular ejection fraction (%) | 46.1 ± 10.7 | 50.2 ± 12.5 | 0.224 |
| Peak pressure gradient (mmHg) | 90.6 ± 24.1 | 86.6 ± 27.9 | 0.641 |
| Mean pressure gradient (mmHg) | 57.7 ± 15.3 | 55.4 ± 15.6 | 0.674 |
| Aortic annulus dimension (mm) | 23.30 ± 5.32 | 22.36 ± 6.85 | 0.141 |
| Aortic bulbus dimension (mm) | 29.70 ± 5.86 | 28.61 ± 7.46 | 0.893 |
| Interventricular septal dimension (mm) | 14.17 ± 3.82 | 13.55 ± 2.46 | 0.627 |
| Aortic regurgitation grade ≥ I, n (%) | 19 (82.6) | 20 (90.9) | 0.692 |
| Mitral insufficiency ≥ grade I, n (%) | 22 (95.7) | 19 (86.4) | 0.247 |
Intraoperative data of pacemaker (PM) and non pacemaker group (N-PM)
| Procedural success, n (%) | 23 (100) | 22 (100) | 0.999 |
| Conversion to surgical AVR, n (%) | 0 (0) | 0 (0) | 0.999 |
| Intraprocedural circulatory depression, n (%) | 4 (17.4) | 2 (9.1) | 0.635 |
| Catecholamine therapy, n (%) | 4 (17.4) | 2 (9.1) | 0.714 |
| Resuscitation, n (%) | 1 (4.4) | 0 (0) | 0.553 |
| Defibrillation, n (%) | 1 (4.4) | 0 (0) | 0.612 |
| Vascular access site complication, n (%) | 5 (21.8) | 4 (18.2) | 0.367 |
| Contrast agent (ml) | 113.3 ± 36.4 | 125.5 ± 60.8 | 0.732 |
| Fluoroscopy time (min) | 25.7 ± 1.8 | 23.9 ± 2.6 | 0.572 |
| Procedure time (min) | 107.7 ± 27.1 | 104.9 ± 33.3 | 0.725 |
| CoreValve, n (%) | |||
| 26mm | 10 (43.5) | 12 (54.6) | 0.112 |
| 29mm | 13 (56.6) | 10 (45.5) | 0.386 |
| Pre TAVI, n (%) | 23 (100) | 22 (100) | 0.999 |
| Post TAVI valvuloplasty, n (%) | 10 (43.5) | 10 (45.5) | 0.566 |
| Number of inflations, n (%) | 1.08 ± 0.75 | 1.14 ± 0.94 | 0.335 |
| Balloon diameter (mm) | 21.87 ± 3.84 | 21.27 ± 4.44 | 0.432 |
| Balloon length (mm) | 55.22 ± 26.81 | 52.73 ± 30.27 | 0.613 |
| Angiographic Aortic insufficiency (grade) | 1.22 ± 0.48 | 1.10 ± 0.62 | 0.725 |
| ICU stay (days) | 2.9 ± 3.2 | 2.5 ± 1.8 | 0.686 |
| Hospital stay (days) | 13.4 ± 11.3 | 12.0 ± 6.5 | 0.237 |
Electrocardiographic characteristics
| Rhythm | |||
| Sinus | 18 (78.3) | 18 (78.3) | 14 (63.7) |
| Atrial fibrillation | 5 (21.8) | 5 (21.8) | 5 (21.8) |
| Heart rate | 72.7 ± 12.6 | 68.5 ± 13.8 | 66.0 ± 16.9 |
| Surface ECG | |||
| PQ interval | 197.1 ± 51.2 | 230.42 ± 40.94 | 243.05 ± 34.59 |
| QRS width | 97.0 ± 15.0 | 139.04 ± 31.86 | 162.96 ± 33.59 |
| QT interval | 388.2 ± 29.3 | 409.91 ± 28.67 | 408.52 ± 23.22 |
| Left-BBB | 0 (0) | 16 (69.6) | 20 (87.0) |
| Right-BBB | 1 (4.35) | 0 (0) | 0 (0) |
| First-degree block | 5 (21.8) | 8 (34.8) | 18 (78.3) |
| Second-degree block # | 0 (0) | 4 (17.4) | 4 (17.4) |
| Complete block | 0 (0) | 4 (17.4) | 6 (26.1) |
| Intracardiac measurement | |||
| SNRT | 1086.8 ± 171.2 | 1093.89 ± 154.58 | 1122.11 ± 154.47 |
| c-SNRT | 487.0 ± 54.3 | 492.94 ± 43.88 | 498.13 ± 42.72 |
| AH interval | 135.5 ± 44.7 | 139.32 ± 36.62 | 153.61 ± 43.40 |
| HV interval | 58.5 ± 12.5 | 74.00 ± 13.51 | 81.68 ± 17.76 |
| Antegrade AV ERP | 410.0 ± 42.6 | 470.00 ± 118.57 | 469.81 ± 45.75 |
| Retrograde AV ERP | 442.6 ± 38.0 | 470.56 ± 45.10 | 494.00 ± 59.33 |
* p-value <0.05.
italic : N-PM-group.
normal: PM-group.
# 2nd degree (type 2) AV-block.
Figure 1Rate of LBBB and AV block in pacemaker and non pacemaker group prior and 7 days after TAVI.
Figure 2AH and HV conduction time in pacemaker and non pacemaker group prior and 7 days after TAVI.